U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C40H47N11O6
Molecular Weight 777.8713
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of UK-432097

SMILES

CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=C(N=C3NCC(C4=CC=CC=C4)C5=CC=CC=C5)C(=O)NCCNC(=O)NC6CCN(CC6)C7=NC=CC=C7

InChI

InChIKey=ZOTHAEBAWXWVID-HXEFRTELSA-N
InChI=1S/C40H47N11O6/c1-2-41-37(54)33-31(52)32(53)39(57-33)51-24-46-30-34(45-23-28(25-11-5-3-6-12-25)26-13-7-4-8-14-26)48-35(49-36(30)51)38(55)43-19-20-44-40(56)47-27-16-21-50(22-17-27)29-15-9-10-18-42-29/h3-15,18,24,27-28,31-33,39,52-53H,2,16-17,19-23H2,1H3,(H,41,54)(H,43,55)(H2,44,47,56)(H,45,48,49)/t31-,32+,33-,39+/m0/s1

HIDE SMILES / InChI
Molecular Formula C40H47N11O6
Molecular Weight 777.8713
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.pharmacodia.com/yaodu/html/v1/chemicals/127d2e587fe09591c67b04c7c7190479.html

UK-432097 is a selective adenosine A2a agonist which was in development with Pfizer as an inhaled treatment for asthma and chronic obstructive pulmonary disease. UK-432097 had been in phase II clinical trials by Pfizer for the treatment of chronic obstructive pulmonary disease (COPD). However, this study was terminated prematurely due to futility based on results of interim analysis.

Originator

Pfizer
420
Curator's Comment: # Pfizer

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 4.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
50 pg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22077102
4500 μg single, respiratory
dose: 4500 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
UK-432097 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1.6%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22077102
unknown, unknown
 UK-432097 blood
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1.4%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26236482
unknown, unknown
 UK-432097 plasma
Rattus norvegicus
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
ABC8
1

CYP27A1
1

ABC1
1

LXRA
1
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
ABC1
1
 yes
ABC8
1
 yes
CYP27A1
1
 yes
LXRA
1
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
Axon MedChem
1193
https://www.axonmedchem.com/product/1193
MolPort
MolPort-042-665-665
https://www.molport.com/shop/molecule-link/MolPort-042-665-665
Sigma Aldrich
PZ0337
http://www.sigmaaldrich.com/catalog/search?term=PZ0337&interface=All&N=0&mode=match%20partialmax&lang=en®ion=US&focus=product
eMolecules
260824358
https://orderbb.emolecules.com/search/#?query=260824358
eMolecules
36745688
https://orderbb.emolecules.com/search/#?query=36745688
PubMed

PubMed

TitleDatePubMed
Structure of an agonist-bound human A2A adenosine receptor.
2011 Apr 15
Patents

Patents

06753322
2
07094769
3

Sample Use Guides

In Vivo Use Guide
Curator's Comment: administered using an atomizer device
Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
Route of Administration: Intratracheal
In Vitro Use Guide
UK-432097 (1uM) potently increased beta-cell proliferation in mouse islets in vitro
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:34:22 UTC 2023
Edited
by admin
on Fri Dec 15 16:34:22 UTC 2023
Record UNII
8L3OAJ1R5A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
UK-432097
Common Name English
.BETA.-D-RIBOFURANURONAMIDE, 1-DEOXY-1-(6-((2,2-DIPHENYLETHYL)AMINO)-2-(((2-((((1-(2-PYRIDINYL)-4-PIPERIDINYL)AMINO)CARBONYL)AMINO)ETHYL)AMINO)CARBONYL)-9H-PURIN-9-YL)-N-ETHYL-
Systematic Name English
UK-432,097
Code English
6-((2,2-DIPHENYLETHYL)AMINO)-9-(N-ETHYL-.BETA.-D-RIBOFURANOSYLURONAMIDE)-N-(2-(N'-(1-(2-PYRIDYL)-4-PIPERIDYL)UREIDO)ETHYL)-9H-PURINE-2-CARBOXAMIDE
Common Name English
Code System Code Type Description
ChEMBL
CHEMBL1096896
Created by admin on Fri Dec 15 16:34:22 UTC 2023 , Edited by admin on Fri Dec 15 16:34:22 UTC 2023
PRIMARY
FDA UNII
8L3OAJ1R5A
Created by admin on Fri Dec 15 16:34:22 UTC 2023 , Edited by admin on Fri Dec 15 16:34:22 UTC 2023
PRIMARY
PUBCHEM
9833519
Created by admin on Fri Dec 15 16:34:22 UTC 2023 , Edited by admin on Fri Dec 15 16:34:22 UTC 2023
PRIMARY
SMS_ID
300000041475
Created by admin on Fri Dec 15 16:34:22 UTC 2023 , Edited by admin on Fri Dec 15 16:34:22 UTC 2023
PRIMARY
WIKIPEDIA
UK-432,097
Created by admin on Fri Dec 15 16:34:22 UTC 2023 , Edited by admin on Fri Dec 15 16:34:22 UTC 2023
PRIMARY
EPA CompTox
DTXSID70431408
Created by admin on Fri Dec 15 16:34:22 UTC 2023 , Edited by admin on Fri Dec 15 16:34:22 UTC 2023
PRIMARY
CAS
380221-63-6
Created by admin on Fri Dec 15 16:34:22 UTC 2023 , Edited by admin on Fri Dec 15 16:34:22 UTC 2023
PRIMARY
DRUG BANK
DB12691
Created by admin on Fri Dec 15 16:34:22 UTC 2023 , Edited by admin on Fri Dec 15 16:34:22 UTC 2023
PRIMARY
Related Record Type Details
ADENOSINE RECEPTOR A2A
TARGET -> AGONIST
Related Record Type Details
Structure of UK-432097
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966